Privium Fund Management B.V. Raises Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Privium Fund Management B.V. grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 14.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 380,586 shares of the biotechnology company’s stock after acquiring an additional 47,230 shares during the quarter. Arrowhead Pharmaceuticals comprises approximately 1.6% of Privium Fund Management B.V.’s portfolio, making the stock its 15th biggest holding. Privium Fund Management B.V.’s holdings in Arrowhead Pharmaceuticals were worth $7,155,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in ARWR. State Street Corp increased its stake in Arrowhead Pharmaceuticals by 8.8% in the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock valued at $123,083,000 after purchasing an additional 516,569 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $2,264,000. Fisher Asset Management LLC increased its stake in Arrowhead Pharmaceuticals by 941.0% during the third quarter. Fisher Asset Management LLC now owns 122,260 shares of the biotechnology company’s stock worth $2,368,000 after acquiring an additional 110,516 shares during the last quarter. Wealthfront Advisers LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $2,060,000. Finally, King Luther Capital Management Corp acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $1,447,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Piper Sandler decreased their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. B. Riley reaffirmed a “buy” rating and issued a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Finally, Citigroup decreased their target price on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $41.44.

Arrowhead Pharmaceuticals Trading Down 3.2 %

NASDAQ:ARWR opened at $15.10 on Wednesday. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The business’s 50 day moving average is $18.83 and its two-hundred day moving average is $20.05. The company has a market cap of $2.07 billion, a PE ratio of -2.92 and a beta of 0.92. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $14.23 and a 52 week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). On average, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now directly owns 272,122 shares in the company, valued at approximately $5,393,458.04. This trade represents a 10.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the transaction, the chief executive officer now owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This trade represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 301,730 shares of company stock worth $5,352,844 in the last three months. 4.30% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.